• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个大型的法国前瞻性 HIV 感染患者队列:Nadis 队列。

A large French prospective cohort of HIV-infected patients: the Nadis Cohort.

机构信息

Nice University - Sofia Antipolis, Hôpital l'Archet, Nice, France.

出版信息

HIV Med. 2009 Sep;10(8):504-11. doi: 10.1111/j.1468-1293.2009.00719.x. Epub 2009 May 19.

DOI:10.1111/j.1468-1293.2009.00719.x
PMID:19486189
Abstract

OBJECTIVES

The aim of this article is to describe the development of a dynamic French cohort of HIV-infected patients, the methodological issues and decisions made, and the characteristics of the patients currently enrolled.

METHODS

Data are collected during medical encounters. Data quality is ensured by automated checks during data capture, by regular controls, by annual assessments, and by ad hoc processes before any scientific analysis is performed.

RESULTS

In September 2007, 10,458 patients representing 59,383 patient-years of follow-up were followed in our centres, including 446 with a first HIV diagnosis in the past year. Among these recently diagnosed patients, 25.6% presented with late diagnosis. Our cohort included 3017 women (28.8%). The women were less likely to be receiving highly active antiretroviral therapy (HAART) than men, and when treated were less likely to be receiving nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Our network includes medical centres in overseas territories (1105 patients living overseas). In this particular population, women represented 38.5% of the patients, and the probable route of infection was heterosexual in 75.7% of the patients. Despite epidemiological and social disparities, more patients had nondetectable viral loads when receiving HAART in overseas departments than in metropolitan France.

CONCLUSION

The Nadis Cohort represents a collaboration of major French HIV treatment centres. In September 2007, the cohort database contained up-to-date information on more than 10,000 patients, of whom a significant proportion were women. As a consequence of the choices made when building the cohort and the efforts made to ensure the quality of the database, scientific studies are regularly performed using this cohort.

摘要

目的

本文旨在描述一个法国 HIV 感染患者的动态队列的发展情况,包括方法学问题和决策,以及目前入组患者的特征。

方法

数据在医疗接触期间收集。通过数据捕获期间的自动检查、定期控制、年度评估以及在进行任何科学分析之前的特别流程,确保数据质量。

结果

截至 2007 年 9 月,我们中心共随访了 10458 名患者,代表了 59383 患者年的随访时间,其中包括 446 名在过去一年中首次诊断为 HIV 的患者。在这些新诊断的患者中,25.6%为晚期诊断。我们的队列包括 3017 名女性(28.8%)。与男性相比,女性接受高效抗逆转录病毒治疗(HAART)的可能性较低,而接受治疗时,她们接受非核苷类逆转录酶抑制剂(NNRTI)为基础方案的可能性较低。我们的网络包括海外领土的医疗中心(1105 名居住在海外的患者)。在这个特定人群中,女性占患者的 38.5%,75.7%的患者感染途径为异性性传播。尽管存在流行病学和社会差异,但在海外部门接受 HAART 的患者中,病毒载量不可检测的患者比例高于法国本土。

结论

Nadis 队列代表了法国主要 HIV 治疗中心的合作。截至 2007 年 9 月,队列数据库包含了超过 10000 名患者的最新信息,其中很大一部分是女性。由于在构建队列时做出的选择以及为确保数据库质量所做的努力,该队列经常用于科学研究。

相似文献

1
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.一个大型的法国前瞻性 HIV 感染患者队列:Nadis 队列。
HIV Med. 2009 Sep;10(8):504-11. doi: 10.1111/j.1468-1293.2009.00719.x. Epub 2009 May 19.
2
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.人类免疫缺陷病毒基因耐药性检测对治疗效果的影响研究。
Verh K Acad Geneeskd Belg. 2001;63(5):447-73.
3
[Medical care for HIV infection in France in 2005, the NADIS cohort study on 7416 patients].[2005年法国的HIV感染医疗护理,NADIS对7416名患者的队列研究]
Med Mal Infect. 2006 Sep;36(9):454-9. doi: 10.1016/j.medmal.2006.07.003. Epub 2006 Oct 6.
4
[Demographic, clinical, immunovirological and therapeutic features of 8714 HIV infected French patients included in the Nadis Hospital Cohorte in 2006].[2006年纳入纳迪斯医院队列研究的8714例法国HIV感染患者的人口统计学、临床、免疫病毒学及治疗特征]
Med Mal Infect. 2008 Jun;38(6):299-308. doi: 10.1016/j.medmal.2008.02.007. Epub 2008 Apr 18.
5
Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.接受基于非核苷类逆转录酶抑制剂或蛋白酶抑制剂的高效抗逆转录病毒治疗方案的患者中,可检测到的HIV病毒血症间歇性发作在发生率和预后方面是相当的。
Clin Infect Dis. 2005 Nov 1;41(9):1326-32. doi: 10.1086/496985. Epub 2005 Sep 29.
6
Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort.原发性HIV-1感染管理的近期变化:法国PRIMO队列研究结果
HIV Med. 2004 Sep;5(5):326-33. doi: 10.1111/j.1468-1293.2004.00231.x.
7
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.一线高效抗逆转录病毒治疗中病毒载量成功抑制后病毒学失败的决定因素。
Antivir Ther. 2008;13(7):927-36.
8
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.塞内加尔接受高效抗逆转录病毒治疗的成年人的死亡率和死亡原因:一项为期7年的队列研究。
AIDS. 2006 May 12;20(8):1181-9. doi: 10.1097/01.aids.0000226959.87471.01.
9
Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000.瑞士HIV感染的临床流行病学与研究:瑞士HIV队列研究(1988 - 2000年)
Schweiz Med Wochenschr. 2000 Oct 14;130(41):1493-500.
10
Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.抗逆转录病毒药物选择对高胆固醇血症事件的影响:核苷类逆转录酶抑制剂主干的作用
HIV Med. 2005 Nov;6(6):396-402. doi: 10.1111/j.1468-1293.2005.00325.x.

引用本文的文献

1
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.间歇性使用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺治疗可使病毒得到抑制的HIV感染者维持高水平的病毒抑制。
J Pers Med. 2023 Mar 27;13(4):583. doi: 10.3390/jpm13040583.
2
High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat'AIDS cohort.高梅毒感染率和发病率在艾滋病毒感染者和暴露前预防使用者中:法国 Dat'AIDS 队列的回顾性研究。
PLoS One. 2022 May 19;17(5):e0268670. doi: 10.1371/journal.pone.0268670. eCollection 2022.
3
Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.
法国抗逆转录病毒药物仿制药对 HIV 患者治疗的经济影响:2019 年至 2023 年之间的模拟。
BMC Health Serv Res. 2022 Apr 27;22(1):567. doi: 10.1186/s12913-022-07859-w.
4
Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.2010 年至 2015 年期间法国 HIV 感染者的宫颈癌、乳腺癌和结直肠癌发病率。
PLoS One. 2022 Mar 25;17(3):e0261069. doi: 10.1371/journal.pone.0261069. eCollection 2022.
5
Seroprevalence of chikungunya virus infection among HIV-infected adults in French Caribbean Islands of Martinique and Guadeloupe in 2015: A cross-sectional study.2015年法属加勒比岛屿马提尼克岛和瓜德罗普岛HIV感染成人中基孔肯雅病毒感染的血清流行率:一项横断面研究。
PLoS Negl Trop Dis. 2021 Apr 9;15(4):e0009267. doi: 10.1371/journal.pntd.0009267. eCollection 2021 Apr.
6
The effects of chikungunya virus infection on people living with HIV during the 2014 Martinique outbreak.基孔肯雅热病毒感染对 2014 年马提尼克岛暴发期间艾滋病毒感染者的影响。
PLoS One. 2020 Jun 5;15(6):e0234267. doi: 10.1371/journal.pone.0234267. eCollection 2020.
7
Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015.2010 年至 2015 年期间,法国 DAT'AIDS 队列中艾滋病毒感染者中的卡波西肉瘤。
J Eur Acad Dermatol Venereol. 2020 May;34(5):1065-1073. doi: 10.1111/jdv.16204. Epub 2020 Apr 30.
8
Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.在乙肝/艾滋病毒合并感染中,含替诺福韦的治疗方案可使 HBsAg 清除率提高。
PLoS One. 2019 Apr 18;14(4):e0215464. doi: 10.1371/journal.pone.0215464. eCollection 2019.
9
Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.法国 HIV 暴露前预防的错失机会:法国 DAT'AIDS 队列的回顾性分析。
BMC Infect Dis. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5.
10
HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat'AIDS cohort.HIV 相关超额死亡率和年龄相关合并症在年龄≥60 岁的 HIV 患者中的研究:法国 Dat'AIDS 队列的相对生存分析。
BMJ Open. 2019 Jan 25;9(1):e024841. doi: 10.1136/bmjopen-2018-024841.